Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 25, 2026
Stoke Therapeutics, Inc. (STOK)
A forensic read on Stoke Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
12.3
Distress distance
Clean
Earnings quality
4
Forensic signals
-8.5
P / E (ttm)
-2.0%
ROE
$1.7B
Market cap
0.00%
Dividend yield
404.5%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Stoke Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 12.3, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-5.9%
FY2025
Return on invested capital.Return on invested capital is -5.9% in the latest fiscal year and rising across FY2023–FY2025 from -1491.0%. After-tax operating profit was ($91M) in FY2023 and ($16M) in FY2025, with operating income at -1307.2% of revenue in FY2023, -277.3% in FY2024 and -11.2% in FY2025. The capital base behind it grew +4444% across FY2023–FY2025, from $6M to $276M, and the return did not fall doing it, so the dollars added over that window earned at least the -1491.0% the older base was already earning.
+16.0%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +35% over the last 2 years to FY2025 (+16.0%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~16.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~26%.
+90.6%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +90.6% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building sharply, and much of it is accounted for. The build is led by receivables up +256% against revenue +405%. That build tracks a +405% revenue year: net operating assets grew +165% and receivables +256%, so the balance sheet is carrying more volume rather than getting heavier per dollar of sales — the accrual build is funding demand the company is shipping, not earnings running ahead of collection. A cash-flow measure on the same base disagrees: reported earnings ran behind operating cash by 28% of net operating assets, against an accruals ratio of 90.6%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.
Key fundamentals
Latest Revenue$184.4M
Revenue Growth YoY+404.5%
Revenue CAGR (2yr)+357.8%
Net Margin-3.7%
Free Cash Flow$44.9M
Return on Equity-2.0%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Stoke Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Sep 25, 2026. Forensic signals flag probability, not certainty.
Stoke Therapeutics, Inc. (STOK) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
17% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 17% of revenue and 72% of free cash flow in FY2025 — about $0.54 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 16.2% a year, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.